These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12480064)

  • 1. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban.
    Schneider DJ; Herrmann HC; Lakkis N; Aguirre F; Wan Y; Aggarwal A; Kabbani SS; DiBattiste PM
    Am J Cardiol; 2002 Dec; 90(12):1421-3. PubMed ID: 12480064
    [No Abstract]   [Full Text] [Related]  

  • 2. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
    Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
    Valgimigli M; Tebaldi M; Campo G; Gambetti S; Bristot L; Monti M; Parrinello G; Ferrari R;
    JACC Cardiovasc Interv; 2012 Mar; 5(3):268-77. PubMed ID: 22440491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
    Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
    Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of glycoprotein IIb/IIIa receptor inhibitor on the microcirculation in patients undergoing high-risk coronary stenting; a prospective, randomized study.
    Wong P; Harding S; Inglessis I; Choi CJ; Walters D; Chang Y; Gimelli G; Jang IK
    J Thromb Thrombolysis; 2003 Dec; 16(3):163-6. PubMed ID: 15087602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
    Talarico GP; Brancati M; Burzotta F; Porto I; Trani C; De Vita M; Todaro D; Giammarinaro M; Leone AM; Niccoli G; Andreotti F; Mazzari MA; Schiavoni G; Crea F
    J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):245-51. PubMed ID: 19262211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
    Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
    Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The glycoprotein IIb/IIIa platelet receptor blocker tirofiban, but not heparin, counteracts platelet aggregation in unstable angina pectoris.
    Mattsson E; Martinsson A; Nyqvist O; Rasmanis G; Sylvén C; Karlberg KE
    Am J Cardiol; 1997 Oct; 80(7):938-40. PubMed ID: 9382012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
    Moriguchi A; Maeda M; Mihara K; Aoki T; Matsuoka N; Mutoh S
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):75-86. PubMed ID: 15678114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited.
    Lakkis N; Lakiss N; Bobek J; Farmer J
    Catheter Cardiovasc Interv; 2002 Aug; 56(4):474-7. PubMed ID: 12124955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban.
    Simon DI; Liu CB; Ganz P; Kirshenbaum JM; Piana RN; Rogers C; Selwyn AP; Popma JJ
    Catheter Cardiovasc Interv; 2001 Apr; 52(4):425-32. PubMed ID: 11285593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
    Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
    Thorac Cardiovasc Surg; 2006 Apr; 54(3):162-7. PubMed ID: 16639676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study.
    Talreja D; Lubbe D; Orford JL; Lennon R; DiBattiste PM; Berger PB
    J Thromb Thrombolysis; 2004 Aug; 18(1):25-30. PubMed ID: 15744550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acute basilar artery thrombosis with a combination of systemic alteplase and tirofiban, a nonpeptide platelet glycoprotein IIb/IIIa inhibitor: report of four cases.
    Junghans U; Seitz RJ; Wittsack HJ; Aulich A; Siebler M
    Radiology; 2001 Dec; 221(3):795-801. PubMed ID: 11719681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW
    J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
    Zhao XQ; Théroux P; Snapinn SM; Sax FL
    Circulation; 1999 Oct; 100(15):1609-15. PubMed ID: 10517731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.